Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated sodium channels (VGSCs) are essential transmembrane proteins that facilitate the rapid influx of sodium ions, driving the depolarization phase of action potentials in excitable tissues. This specific group comprises Nav1.7, Nav1.8, and Nav1.5, which are distinguished by their unique tissue distribution and physiological roles. Nav1.7 and Nav1.8 are primarily localized in the peripheral sensory neurons of the dorsal root ganglia, where they act as critical gatekeepers for pain signaling and nociception [UniProt Q15858, Q9Y5Y9]. In contrast, Nav1.5 is the predominant isoform in cardiac myocytes, essential for maintaining normal heart rhythm and electrical conduction [UniProt Q14524]. Therapeutic interest in Nav1.7 and Nav1.8 has surged due to their potential as targets for novel non-opioid analgesics, particularly for treating neuropathic and inflammatory pain [PubMed PMC6135004]. However, a major challenge in developing these analgesics is achieving high selectivity to avoid cross-reactivity with Nav1.5, which can cause life-threatening cardiotoxicity, or with CNS-resident channels that cause neurological impairment [StatPearls NBK540971]. Drugs like lidocaine act as non-selective blockers for anesthesia, while newer agents like suzetrigine (VX-548) are designed to target Nav1.8 with high specificity to improve safety [NEJM 2024]. Understanding the structural differences between these isoforms is vital for the design of precision medicines that manage pain without compromising cardiac or central nervous system function.
Inhibition of the alpha-subunit pore to prevent sodium ion influx, thereby suppressing membrane depolarization and action potential generation in neurons or myocytes [PubChem, StatPearls NBK540971].
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium channel protein type 9 subunit alpha (Nav1.7), Sodium channel protein type 10 subunit alpha (Nav1.8), and Sodium channel protein type 5 subunit alpha (Nav1.5) (Nav1.7/Nav1.8/Nav1.5).